復星醫藥A股封漲停板 H股漲超11% 均創階段新高
格隆匯4月28日丨隨着印度公佈單日新增確診突破36萬例再傳記錄,部分抗疫概念股午後快速拉昇,其中,復星醫藥A股封漲停板報53.55元,創今年1月初以來新高;H股漲超11%報45.2港元,創2018年6月以來新高;復星醫藥最新市值1283億元人民幣。公司26日晚公佈業績顯示,一季度收入80.56億(+37%)、淨利潤8.47億(+46.78%)、扣非淨利潤6.58億元(+50.76%),均取得恢復性增長,且超市場預期。


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.